GlassScriptPhysician profile
Paresh Mehta
NPI 1144494451
$2,523.38
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $605 · 2020: $184 · 2021: $570 · 2022: $598 · 2023: $469 · 2024: $96.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $566.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,094.33 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $265.07 | 2019-2024 | Xifaxan |
| Janssen Biotech, INC. | $231.83 | 2019-2024 | Stelara |
| Celgene Corporation | $214.34 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $124.30 | 2022 | |
| Lupin INC. | $122.27 | 2019 | |
| Gilead Sciences, INC. | $117.69 | 2019-2023 | |
| Boston Scientific Corporation | $98.98 | 2019 | |
| Horizon Therapeutics Plc | $40.16 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $39.60 | 2023 | |
| Amag Pharmaceuticals, INC. | $33.61 | 2021-2022 | |
| Pfizer INC. | $30.26 | 2019 | |
| Aimmune Therapeutics, INC. | $22.92 | 2024 | |
| Ironwood Pharmaceuticals, INC | $22.57 | 2023 | Linzess |
| Olympus America INC. | $18.83 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $18.33 | 2020 | |
| Braintree Laboratories, INC. | $12.31 | 2020 | |
| Endogastric Solutions, INC | $8.17 | 2023 | Esophyx |
| Qol Medical, LLC | $7.81 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$85,307.35 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paresh Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.